Transfusion-transmitted infections remain a public health challenge in India despite mandatory ELISA screening. Evaluate the feasibility and ethical implications of mandating Nucleic Acid Testing (NAT) in Indian blood banks.

Q. Transfusion-transmitted infections remain a public health challenge in India despite mandatory ELISA screening. Evaluate the feasibility and ethical implications of mandating Nucleic Acid Testing (NAT) in Indian blood banks. (15 marks, 250-350 words)

India mandates serological screening of every donation for five transfusion-transmissible infections — HIV, HBV, HCV, syphilis and malaria [2]. Yet ELISA detects antibodies, not virus, leaving a window period of infectivity. NAT closes that gap, but mandating it is a question of feasibility, not merely of science.

Case for mandating NAT - Scientific superiority: NAT amplifies viral RNA/DNA directly, sharply shortening the HIV and HCV window periods that ELISA cannot cover [1]. - Demonstrated Indian evidence: the Madhya Pradesh centralised hub-and-spoke PPP model screened 1,58,493 seronegative samples and found 943 (1 in 168) NAT-reactive, potentially averting 2,829 infections [1]. - Proven delivery model: centralised hubs serving satellite centres avoid equipping every licensed blood bank, making scale-up administratively tractable [1]. - WHO treats a quality-assured, universally screened blood supply as a core state obligation [4].

Feasibility constraints - Fiscal: NAT costs several times ELISA per unit; health delivery is a State List subject (Entry 6, List II), and the Supreme Court (March 2026) declined a mandate precisely citing states' financial constraints and judicial lack of expertise [6]. - Infrastructure: molecular platforms, cold chain and trained technicians are concentrated in urban tertiary centres, not district blood banks [3]. - Legal route: a mandate requires amending blood-bank standards under the Drugs and Cosmetics Act, 1940 — an executive, expert-led act, not a judicial one [2].

Ethical implications - Right to health under Article 21 and the precautionary principle favour maximal safety; but resource-allocation ethics demand weighing NAT against competing health needs. - Equity: with roughly 1–1.5 lakh thalassemia-major children and 10,000–15,000 born annually [5], transfusion-dependent patients bear cumulative risk — uneven NAT access creates a two-tier blood supply. - Higher processing charges could exclude poor patients, whereas 100% voluntary non-remunerated donation remains the cheaper first-order safety duty [3][4].

An immediate universal mandate is neither fiscally nor administratively feasible; a phased, NBTC-led centralised rollout — prioritising thalassemia day-care centres and high-volume hubs, funded through the National Health Mission and PPP hubs — is. Sequenced this way, NAT converts Article 21's promise of safe blood into a graded, funded and attainable entitlement.

(~330 words)

Sources: 1. Blood Safety: The Madhya Pradesh Centralized Nucleic Acid Testing (NAT) Model for Blood Donor Screening (Cureus/PMC, 2026) — window-period detection; 1 in 168 seronegative samples NAT-reactive; hub-and-spoke PPP model 2. Standards for Blood Banks, National Blood Transfusion Council (NBTC), MoHFW — mandatory serological screening for five TTIs; standards issued under the Drugs and Cosmetics Act framework 3. Access to Safe Blood — National AIDS Control Organisation (NACO), MoHFW — blood bank infrastructure and voluntary donation policy 4. Blood safety and availability — WHO Fact Sheet — state obligation for quality-assured screening and voluntary non-remunerated donation 5. Vice President on the burden of genetic diseases — Press Information Bureau — 1–1.5 lakh thalassemia-major children; 10,000–15,000 affected births annually 6. "SC declines plea to make nucleic acid tests compulsory", The Hindu, 14 March 2026 — Supreme Court refusal, institutional-competence and state-cost reasoning